Clinical Trials
17 trialsNCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT07242547 2026-05-05
MERLIN
Fundación GECP
Phase 2 Recruiting
NCT03803787 2026-04-08
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Instituto Nacional de Cancerologia de Mexico
Phase 2 Recruiting
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT07205536 2025-12-11
ANC-IIT-004
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06758700 2025-12-05
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06917573 2025-11-19
PALACE
Fundación GECP
Phase 2 Recruiting
NCT04776447 2025-04-09
APOLO
Fundación GECP
Phase 2 Active not recruiting
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT02904954 2023-10-11
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn
NCT04725448 2021-04-06
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04371796 2020-05-01
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02941601 2019-09-27
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Withdrawn
NCT03389256 2018-01-03
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown